Anatomical Context
The corpora cavernosa are the paired cylindrical erectile chambers that occupy the dorsolateral penile shaft. Each corpus cavernosum is enclosed within the tunica albuginea and contains a spongy network of sinusoidal spaces lined by smooth muscle and endothelium — the cavernous tissue that fills with arterial blood during erection. In organic erectile dysfunction, haemodynamic inflow failure (vasculogenic ED), cavernous smooth muscle fibrosis (post-radical prostatectomy neuropraxia, diabetes), or venous leak prevents adequate intracorporal pressure from developing. The inflatable penile prosthesis bypasses this haemodynamic failure entirely by replacing the corporal filling mechanism with a hydraulic system.
The three-piece IPP consists of paired inflatable cylinders placed within the corpora cavernosa, a fluid reservoir placed in the retropubic space (space of Retzius) or sub-fascially beneath the external inguinal ring, and a three-way pump-valve mechanism positioned in the dependent scrotum. Saline fluid is transferred from the reservoir to the cylinders via the pump to produce rigidity; deflation transfers fluid back to the reservoir, restoring the flaccid state. All components are entirely intracorporeal — nothing is externally visible or palpable except the scrotal pump, which is discreetly positioned within scrotal tissue.
The corpus spongiosum — carrying the urethra along the ventral penile midline — is not entered during IPP implantation. The scrotal septum separates the two hemiscrotums and provides the anatomical compartment for pump placement. The reservoir sits posterior to the rectus abdominis in the retropubic space or, in patients with prior pelvic surgery, sub-fascially to avoid the scarred retropubic field.
What the Procedure Involves
The procedure is performed through either a penoscrotal or infrapubic incision. The penoscrotal approach, made at the penoscrotal junction, provides excellent access to the corpora and scrotal pump position and is the most widely used approach for primary implantation. The infrapubic approach, made just above the penile base, provides direct access to the retropubic reservoir space and is favoured by some surgeons for concurrent Peyronie's correction or in specific anatomical circumstances.
Corporotomy incisions are made bilaterally in the tunica albuginea. Each corpus cavernosum is dilated proximally toward the crural base and distally toward the glans using serial Hegar dilators, creating the intracorporal channel that accommodates the cylinder. Cylinder length is measured precisely — accurate sizing is critical to avoid the complications of over- or under-sizing. The paired cylinders are inserted, their rear tips seated at the corporotomy, and the proximal ends positioned at the crura. The corporotomy incisions are closed with absorbable sutures around the cylinder input tubes.
The reservoir is placed through a small fascial incision into the retropubic space or sub-fascial position, filled with a defined volume of isotonic saline, and connected via tubing. The scrotal pump is positioned in the dependent scrotum through the same penoscrotal incision, and all tubing connections are made under direct vision and tested for fluid-tight integrity. The device is cycled intraoperatively to confirm correct inflation and deflation before wound closure.
Candidacy Criteria
The primary indication for IPP implantation is organic erectile dysfunction refractory to, or intolerant of, oral PDE5 inhibitor therapy (sildenafil, tadalafil, vardenafil), intraurethral alprostadil, and intracavernosal injection therapy. Specific patient populations with high rates of IPP candidacy include men with post-radical prostatectomy neuropraxic ED, diabetic vasculogenic ED unresponsive to medical therapy, Peyronie's disease with concurrent ED, and men with severe cavernous fibrosis from prior priapism or multiple failed injection attempts. IPP is also the surgical procedure of choice for Peyronie's disease when curvature and ED coexist, as the inflated cylinders mechanically straighten the corpora and may be combined with limited plaque management.
Contraindications include active urinary tract infection, cutaneous infection at the operative site, untreated coagulopathy, and anatomical conditions precluding safe reservoir placement (in which case a two-piece IPP or malleable prosthesis may be considered). Patients with severe neurological impairment affecting manual dexterity who cannot reliably operate the scrotal pump mechanism are candidates for a malleable (semi-rigid) prosthesis rather than a three-piece IPP.
Recovery Timeline
Post-operative discomfort is typically mild to moderate and is managed with oral analgesics for 5 to 7 days. Scrotal swelling and ecchymosis peak at 48 to 72 hours and resolve progressively over 2 to 3 weeks. Patients are encouraged to ambulate the same day of surgery. Return to sedentary work is typically possible within 7 to 14 days. Strenuous physical activity is restricted for 4 weeks. The device is left in the deflated (flaccid) state throughout the initial healing period.
Device activation — the first supervised inflation and deflation of the prosthesis — is performed at the 4 to 6-week post-operative visit under surgeon instruction. Patients are trained in pump operation (identifying the pump in the scrotum, cycling the three-way valve from inflate to deflate) until independent operation is confirmed. Sexual activity, including intercourse, is cleared at the same visit once activation is complete and wound healing is confirmed. There are no restrictions on frequency or duration of device use once fully healed, and the device can be inflated for extended periods without clinical concern.
Risks and Complication Profile
Infection is the most feared complication of IPP implantation. In primary implantation with modern antibiotic-impregnated (InhibiZone — rifampin/minocycline coating, Boston Scientific AMS 700) or hydrophilic-coated (Coloplast Titan) devices, infection rates are reported at 1 to 3% in large registry studies. Device infection typically requires complete device removal, a period of antibiotic treatment, and salvage reimplantation — a more technically demanding procedure with higher complication rates than primary implantation. Mechanical failure — cylinder aneurysm, tubing kink, pump malfunction, reservoir herniation — occurs in approximately 5 to 10% of devices at 10 years, reflecting the mechanical wear inherent to any hydraulic system used for sexual activity. Revision surgery for mechanical failure has a high success rate.
Auto-inflation — spontaneous device inflation without patient-initiated pump activation — occurs occasionally and is usually managed by pump cycle adjustment or, rarely, reservoir revision. Cylinder erosion through the urethral or corporal wall is rare (less than 1%) in primary implantation and more common in patients with prior pelvic radiation or severe cavernous fibrosis. Sensory changes are uncommon with the penoscrotal approach if the dorsal neurovascular bundle is not disturbed.
Cost Considerations
The total cost of $15,000 to $25,000 reflects four major components: surgeon's professional fee, outpatient facility or hospital fee, anaesthesia, and the device itself. The AMS 700 (Boston Scientific) and Coloplast Titan — the two dominant FDA-cleared three-piece IPP devices — have a wholesale device cost of approximately $5,000 to $10,000 per unit, which is reflected in the procedure pricing. The antibiotic or hydrophilic surface coating variants carry a modest premium over uncoated versions.
Unlike purely aesthetic procedures, IPP implantation for documented organic erectile dysfunction may qualify for partial or full insurance coverage under major medical plans and Medicare. Coverage determination depends on documentation of organic aetiology, prior treatment failure, and the specific insurer. Patients should request pre-authorisation through their surgeon's billing department prior to scheduling, as out-of-pocket cost can vary dramatically depending on coverage status.
Selecting a Qualified Surgeon
IPP implantation requires specific procedural training beyond general urology. The procedure involves precise corporal dilation, accurate cylinder sizing, retroperitoneal reservoir placement, and tubing connection under tension — each step with distinct potential complications if performed incorrectly. Surgeons should hold ABU board certification, active SMSNA membership, and documented training in prosthetic urology. An andrology fellowship with specific IPP implantation volume is the strongest credential. Manufacturers of FDA-cleared devices (Boston Scientific, Coloplast) also maintain certification programmes for surgeon proctoring and training.
Procedure volume is a strong predictor of outcome in prosthetic urology. High-volume implanters (greater than 50 cases per year) consistently demonstrate lower infection rates, lower revision rates, and faster operative times than low-volume surgeons. Patients should ask directly about annual case volume, primary versus revision case mix, and device brand preference — surgeons who implant both major device platforms can provide an unbiased recommendation for the individual patient's anatomy and lifestyle.